Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Characterization of celecoxib-loaded solid lipid nanoparticles formulated with tristearin and softisan 100

Ehab A Fouad^1,2 , Alaa Eldeen B Yassin^3,4, Hamdan N Alajami⁵

¹Department of Pharmaceutics, Almaarefa Colleges for Science and Technology, P.O Box 71666, Riyadh 11597, Saudi Arabia; ²Department of Pharmaceutics, Faculty of Pharmacy, Assiut University 71526, Assiut, Egypt; ³Pharmaceutical Sciences Department, College of Pharmacy-3163, King Saud bin Abdulaziz University for Health Sciences, and King Abdullah International Medical Research Center, Ministry of National Guard, Health Affairs, Riyadh 11426, Saudi Arabia; ⁴Department of Pharmaceutics, Faculty of Pharmacy, AlAzhar University, Cairo, Egypt; ⁵Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, PO Box 3354 Riyadh 11211, Saudi Arabia.

For correspondence:- Ehab Fouad Email: bahe2004@yahoo.co.uk Tel:+966553889130

Received: 22 September 2014 Revised: 1 January 2015 Published: 28 February 2015

Citation: Fouad EA, Yassin AE, Alajami HN. Characterization of celecoxib-loaded solid lipid nanoparticles formulated with tristearin and softisan 100. Trop J Pharm Res 2015; 14(2):205-210 doi: 10.4314/tjpr.v14i2.3

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To prepare solid lipid nanoparticles employing softisan 100 (SOFTI) or tristearin (TS) as solid lipid carriers for celecoxib (CXB) to overcome its dissolution challenge.

Methods: The solid lipid nanoparticles (SLN) of CXB were prepared by ultrasonic melt-emulsification technique. SLN was characterized using differential scanning calorimetry (DSC), Fourier transform infra spectroscopy (FTIR), as well as for entrapment efficiency, particle size, zeta potential and CXB release.

Results: The SLN formulations exhibited high CXB entrapment efficiency (91.6 % for SOFTI and 94.6 % for TS) while mean particle size was 181.0 ± 4.6 and 346.3 ± 3.8 nm for SOFTI and TS, respectively. The DSC thermograms showed the disappearance of CXB peak due to its molecular distribution in the lipid nanoparticles while FTIR spectra revealed physical interaction of CXB with the tested lipids. The tendency of SOFTI to liberate CXB in 24 h was higher than that of TS (55.5 ± 1.07 vs 49.2 ± 2.94 %, p < 0.05). Drug release was by non-Fickian mechanism.

Conclusion: Formulation of CXB in SLN using TS or SOFTI produces sustained drug release delivery that can overcome the dissolution limitation of the drug and thus, improve its therapeutic efficacy.

Keywords: Celecoxib, Solid lipid nanoparticles, Tristearin, Softisan, Dissolution limitation, Sustained drug release